Nipocalimab shows sustained disease control in adolescents with myasthenia gravis in Phase 2/3 study
Summary: Janssen-Cilag International NV announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab, an investigational treatment for adolescents aged 12-17 with generalized myasthenia gravis. This is the first FcRn blocker to show sustained disease control over 24 weeks in this age group.
Participants receiving nipocalimab alongside standard care experienced a significant reduction in immunoglobulin G levels and improved disease activity scores. The treatment was well-tolerated, with no serious adverse events reported during the six-month study.
These findings expand the understanding of nipocalimab's effectiveness in younger patients, where treatment options are currently limited. The results will be presented at the AANEM Annual Meeting in Savannah, Georgia.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings